12.55
+0.59(+4.93%)
Currency In USD
Address
ONE Copley Parkway
Chapel Hill, NC 27560
United States of America
Phone
919 855 2100
Website
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
April 04, 1994
| Name | Title | Pay | Year Born |
| Christopher T. Giordano | Chief Executive Officer, President & Director | 928,591 | 1975 |
| Stuart Rich | Chief Medical Officer & Director | 548,044 | 1950 |
| Douglas Hay | Executive Vice President of Regulatory Affairs | 0 | N/A |
| Doug Randall | Chief Business Officer | 0 | N/A |
| Thomas A. McGauley | CFO and Principal Financial Officer & Principal Accounting Officer | 0 | 1973 |
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.